Prescription medicine
Sodium iodide i 123
Sodium iodide i 123 is a prescription medicine with an FDA approval on record since 1976. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
Check it at the source: the sodium iodide i 123 FDA label on DailyMed (effective April 17, 2018, Cardinal Health 418, Inc); the NDA 17630 record on Drugs@FDA; every sodium iodide i 123 label on DailyMed.
Highlights of the record
FDA label of April 17, 2018; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageAND USE Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
Forms and strengths
Gelatin-coated capsule.
On the market
- Earliest approval on file
- March 24, 1976 Sodium Iodide I 123, Ge Healthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first February 28, 1989; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 1 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 939 through July 30, 2026
What is sodium iodide i 123 used for?
From the label: indications and usageAND USE Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
Source: FDA drug label (Sodium Iodide I 123), Cardinal Health 418, Inc, effective April 17, 2018 (SPL set 50415c27-1928-4307-b1dc-648f47edf65d), via openFDA; the full label on DailyMed
Is there a generic for sodium iodide i 123?
The FDA approved the first generic sodium iodide i 123 on February 28, 1989. 2 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists sodium iodide i 123 from 1 labeler under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1976 earliest approval on file
- 1989 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for sodium iodide i 123?
The FDA Adverse Event Reporting System holds 939 reports that list sodium iodide i 123 among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 46 are coded as a death and 62 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Sodium iodide i 123 side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other